Get the Stockscreener App
1.375
2.83%
-0.04
After Hours:
1.42
0.045
+3.27%
Enveric Biosciences Inc stock is traded at $1.375, with a volume of 167.24K.
It is down -2.83% in the last 24 hours and down -40.22% over the past month.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.
See More
Previous Close:
$1.415
Open:
$1.44
24h Volume:
167.24K
Relative Volume:
0.05
Market Cap:
$5.54M
Revenue:
-
Net Income/Loss:
$-8.22M
P/E Ratio:
-0.0503
EPS:
-27.3467
Net Cash Flow:
$-8.01M
1W Performance:
+3.38%
1M Performance:
-40.22%
6M Performance:
-63.04%
1Y Performance:
-90.76%
1-Day Range:
$1.36
$1.5199
1-Week Range:
$1.26
$1.5199
52-Week Range:
$1.26
$17.64
Enveric Biosciences Inc Stock (ENVB) Company Profile
Name
Enveric Biosciences Inc
Sector
Industry
Phone
(617) 444-8400
Address
245 FIRST STREET RIVERVIEW II 18TH FLOOR, CAMBRIDGE
Compare ENVB vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ENVB
Enveric Biosciences Inc
|
1.375 | 5.70M | 0 | -8.22M | -8.01M | -27.35 |
VRTX
Vertex Pharmaceuticals Inc
|
499.65 | 124.70B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
631.81 | 66.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
912.46 | 55.17B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
192.62 | 38.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
293.52 | 38.90B | 4.29B | 577.22M | 641.34M | 4.2086 |
Enveric Biosciences Inc Stock (ENVB) Latest News
Enveric Biosciences Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit - Business Wire
Enveric Biosciences Company Profile & Introduction - Moomoo
Enveric Biosciences, Inc. Actuals & Estimates (NASDAQ:ENVB) - TradingView
FDA Fast-Tracks Psychedelic Research After Trump’s Executive Order — CMPS, HELP Stocks Gain - Stocktwits
Enveric Biosciences Inc (ENVB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Enveric Biosciences Inc (ENVB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Enveric Biosciences Inc (ENVB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Enveric Biosciences Inc (ENVB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
ENVERIC BIOSCIENCES INC (ENVB) Stock Chart - ChartMill
Enveric Biosciences Inc (ENVB) Institutional Confidence - TradingKey
Enveric Biosciences Inc (ENVB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Enveric Biosciences Inc (ENVB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Enveric Biosciences Inc (ENVB) Valuation: PE, PB & Fair Value Analysis - TradingKey
Enveric Biosciences Inc (ENVB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Enveric Biosciences Announces Participation in 2026 BIO International Convention - Investing News Network
Enveric Biosciences Inc Annual Shareholders Meeting Transcript - GuruFocus
ENVB SEC FilingsEnveric Biosciences Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Enveric Biosciences Expands At-The-Market Equity Offering - TipRanks
Enveric Biosciences (NASDAQ: ENVB) expands $2.4M at-the-market stock program - Stock Titan
Enveric Biosciences (ENVB) amends ATM; $2.425M remaining capacity - Stock Titan
Enveric Biosciences to Participate in the UBS 3rd Virtual CNS Day - Investing News Network
Enveric Biosciences Releases Updated Investor Presentation Materials - TipRanks
Enveric Biosciences posts investor presentation on website under Regulation FD - TradingView
Enveric Biosciences (NASDAQ: ENVB) furnishes Q2 2026 investor presentation - Stock Titan
Enveric Biosciences Announces Withdrawal Of Petition Against Its Patent — ENVB Stock Rises - Stocktwits
ENVB News | ENVERIC BIOSCIENCES INC (NASDAQ:ENVB) - ChartMill
[Form 4] Enveric Biosciences, Inc. Insider Trading Activity - Stock Titan
Enveric Biosciences (ENVB) CFO awarded 133,333 RSUs in long-term equity grant - Stock Titan
Enveric Biosciences (ENVB) CEO granted 201,124 RSUs under 2020 long-term plan - Stock Titan
Enveric Biosciences (ENVB) director receives 18,518 restricted stock shares as equity grant - Stock Titan
Director at Enveric Biosciences (ENVB) receives 18,518 restricted shares - Stock Titan
Enveric (ENVB) awards director Marcus Schabacker 18,518 restricted shares - Stock Titan
Enveric Biosciences (ENVB) awards 25,000 RSUs to its CIO - Stock Titan
Enveric Biosciences (ENVB) Launches Critical Safety Studies for EB-003 - GuruFocus
Enveric Biosciences Initiates Investigational New Drug -enabling Genotoxicity Studies of Lead Neuroplastogen Candidate EB-003 - Investing News Network
Enveric Biosciences stock rises on genotoxicity study launch By Investing.com - Investing.com India
Enveric Biosciences stock rises on genotoxicity study launch - Investing.com
Enveric Biosciences begins genotoxicity studies for EB-003 - Investing.com
Enveric Biosciences begins genotoxicity studies for EB-003 By Investing.com - Investing.com Canada
Enveric Biosciences Initiates Investigational New Drug (IND)-enabling Genotoxicity Studies of Lead Neuroplastogen Candidate EB-003 - Business Wire
Enveric Biosciences (NASDAQ: ENVB) holders OK reverse split, block share increase - Stock Titan
Enveric Biosciences Holds Near Support Amid Modest PullbackPCR Moving Average - thelegaladvocate.com
Enveric Biosciences Stock Slips as Cash Questions Hang Over ENVB - Bez Kabli
ENVB Stock Price, Quote & Chart | ENVERIC BIOSCIENCES INC (NASDAQ:ENVB) - ChartMill
Enveric Biosciences Inc. (ENVB) Q4 2024 Earnings: Massive EPS Miss Highlights Ongoing Cash Burn and No Revenue - thelegaladvocate.com
Enveric Biosciences (ENVB) Achieves Key Milestone in Neuropsychi - GuruFocus
Enveric Biosciences Reports Positive Preclinical Results from Phototoxicity Analysis for Lead Neuroplastogen Candidate EB-003 - Investing News Network
Enveric Biosciences Reports Financial Results and Provides Corporate Update for First Quarter 2026 - BioSpace
Enveric Biosciences 1Q Loss/Shr $1.08 >ENVB - Moomoo
Enveric Biosciences Inc Stock (ENVB) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):